Key result
GHRH agonists promote post-MI cardiac recovery and islet survival, while antagonists counteract tumoral growth.
Answers are grounded in this paper and cite their sources.
Growth Hormone-Releasing Hormone (GHRH) is secreted by the hypothalamus and regulates the release of growth hormone from the anterior pituitary gland. In addition to its endocrine role, this peptide has been shown to act as a growth factor in diverse malignancies. Recent studies indicate that GHRH is also a regulator of several important physiological processes. These processes which include the regulation of the metabolism of the reactive oxygen and nitrogen species are similarly enhanced by GHRH agonists. In contrast, GHRH antagonists can counteract the growth factor effects of GHRH. GHRH and its agonists have been shown to contribute to the recovery of heart tissue after myocardial infarction and can promote the survival and proliferation of pancreatic islets after transplantation into diabetic animals.
No takes yet. Share an insight, caveat, or question.
Barabutis et al. (2010) conducted a review in Malignancies, myocardial infarction, and diabetes. Growth Hormone-Releasing Hormone (GHRH) agonists and antagonists was evaluated. GHRH and its agonists promote cardiac recovery after myocardial infarction and pancreatic islet survival, whereas GHRH antagonists counteract malignancy growth factor effects.
Synapse has enriched 10 related papers. Consider them for comparative context: